Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, a...
Guardado en:
Autores principales: | Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1aee86c84bb84dbda67d66b5890094d6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Paola Ulivi, et al.
Publicado: (2021) -
Latin America in the 21st century nations, regionalism, globalization /
por: Gardini, Gian Luca
Publicado: (2009) -
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
por: Neel I. Nissen, et al.
Publicado: (2021) -
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
por: Dominiek Smeets, et al.
Publicado: (2018) -
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
por: Kiss S, et al.
Publicado: (2018)